Why I’m staying away from BZAI: China exposure + specific short-seller red flags

Not financial advice. I’m not making any accusation of fraud, and I’m not saying the short reports are proven. I’m just explaining why BZAI is outside my risk tolerance.

BZAI has an interesting edge AI / AI chip story, but I’m avoiding it mainly for two reasons: heavy China/APAC-linked exposure and recent short-seller scrutiny around specific counterparties.

**1. China/APAC concentration risk**

For a U.S.-listed company operating in sensitive areas like AI chips, edge AI infrastructure, smart cities, public safety, and potentially defense-adjacent use cases, I see heavy China/APAC-linked revenue and partner exposure as a serious long-term overhang.

Even if the technology is real, U.S. investors may apply a permanent discount if a major part of the growth story depends on opaque China-linked customers, Hong Kong intermediaries, or APAC channel partners.

**2. Pelican Way Research vs. NeoTensr**

One of the biggest red flags for me is the NeoTensr situation.

Blaize announced a contract with NeoTensr expected to generate up to $50 million in revenue within the first year, and also said the partnership built on more than $20 million of NeoTensr-related orders recognized in Q4 2025.

Pelican Way Research later published a short report questioning that deal. The main issue, as I understand it, is whether NeoTensr had enough operating history, capital, and transparency to support such a large transaction. Again, I’m not saying Pelican Way is right — but when a small-cap company’s guidance depends heavily on a young, low-transparency counterparty, I view that as a major risk.

**3. White Diamond Research vs. Starshine / NeoTensr**

White Diamond Research also published a negative report on BZAI and raised red flags around the company’s large customer announcements.

The Starshine agreement is especially important because Blaize previously announced that Starshine Computing Power Technology Limited, a Hong Kong company, had agreed to deliver a minimum of $120 million in revenue over the first 18 months of the agreement.

White Diamond questioned the quality and credibility of that Starshine relationship, and also raised concerns around NeoTensr. I’m not treating short-seller claims as facts, but I do think these reports highlight exactly the kind of customer-quality risk that matters for BZAI.

**4. Why I’m avoiding it**

The combination is what bothers me:

* U.S.-listed AI chip / edge AI company
* Sensitive sectors: AI infrastructure, smart cities, public safety, edge inference
* Heavy China/APAC-linked growth story
* Large headline contracts with relatively opaque counterparties
* Public short reports specifically questioning NeoTensr and Starshine
* Dilution and cash burn risk
* Risk that headline contracts may not become high-quality cash collections

Maybe BZAI proves the skeptics wrong with real revenue, clean cash collections, strong gross margins, and more transparent U.S./allied-market customers. But until then, this looks too risky for me.

I have no position and I’m staying away. Do your own due diligence.